What Is Peptide Therapy? A Clear Guide

A small number of peptides are approved prescription medicines. Semaglutide is authorised in the EU as both Ozempic, for type 2 diabetes, and Wegovy, for weight management — two separate authorisations for the same active substance, each tied to its own brand, formulation, and indication. Tirzepatide is authorised as Mounjaro. Bremelanotide, also known as PT-141, is FDA-approved in the United States as Vyleesi for a specific diagnosis: hypoactive sexual desire disorder in premenopausal women.^[1][2][3][4]

Approval is jurisdiction-specific. Tesamorelin is FDA-approved in the United States, sold as Egrifta, for a defined indication. The manufacturer withdrew its EU marketing-authorisation application for the same peptide in 2012, so tesamorelin does not currently hold an EU authorisation. A peptide can be an approved medicine in one country and unauthorised in another; approved only means something relative to a specific regulator.^[5][6]

A second, much larger group of products is marketed under the same phrase by wellness clinics, anti-ageing practices, and compounding pharmacies. Many of the peptides offered this way — BPC-157 is the most searched example — are not approved medicines anywhere and do not carry a marketing authorisation. Offering a compound as therapy does not by itself change its regulatory status.

In the United States, a nomination to add BPC-157 to the FDA's list of substances that compounding pharmacies may use was reviewed and later withdrawn. The FDA's review noted that compounded BPC-157 may carry immunogenicity risk depending on the route of administration, that peptide-related impurities and active-ingredient characterisation were unresolved, and that available safety information was insufficient to know whether it would cause harm in people.^[7]

The pattern is similar in the EU. A compounded or clinic-mixed peptide blend is not the same thing as a centrally authorised medicine, and it will not appear in the EMA's public register of authorised medicines, regardless of how the clinic describes it.^[9]

A third use of the phrase covers peptides sold explicitly for laboratory research — the category Peptyds operates in. These compounds are not medicines, are not clinically evaluated for the claims sometimes made about them online, and are not sold, marketed, or intended for use in or on the human body. Calling a research peptide a therapy misstates what the supplier is actually providing: a reagent for a laboratory, not a treatment for a person.

Research use only has a specific meaning in the broader drug-development pipeline: it sits before any clinical study in people, and well before the multi-phase evaluation a compound needs to pass to become an approved medicine. Treating a research peptide as either an approved medicine or a clinic's compounded offering skips over that entire evaluation process.^[8]

The fastest check is not the word therapy but the product's actual status. An approved medicine has a public regulatory record: an EPAR from the EMA, or an FDA-approved label, tied to a specific brand name, formulation, and indication. A compounded clinic offering will not have that record, even when the underlying peptide is well known. A research peptide will say so on its own label and documentation, with no clinical claim attached.

This is a matter of checking a public source, not a judgment call. The EMA and national regulators publish authorisation status, the FDA publishes drug labels and its compounding bulk-substance reviews, and a legitimate research supplier documents research use only plainly, with a batch Certificate of Analysis, rather than with a treatment claim.

The three categories are not just paperwork. They carry different evidence bases: an approved medicine went through a multi-phase evaluation before a regulator signed off; a clinic's compounded offering usually has far less product-specific evidence behind the particular way it is being sold; a research peptide has not been evaluated for use in people at all, by design. Treating all three as equally proven because they share one label — peptide — is the actual source of the confusion the phrase creates.

Peptyds sells research peptides, not medicines, and makes no claim that any product it lists treats, prevents, or cures a condition. Working out which of the three meanings of peptide therapy applies to a given product is a more useful question than whether the word therapy appears on the page.